Reviva Pharmaceuticals Stock Plummets on Funding Concerns

Reviva Pharmaceuticals shares are trading lower after the FDA recommended a second Phase 3 clinical trial for brilaroxazine, with analysts from Roth Capital expecting the need for an additional $60M to $75M funding, a significant amount relative to its market cap, despite maintaining a Buy rating and a $3 price target.